Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) Research & Development (2023 - 2025)

Metagenomi (MGX) has disclosed Research & Development for 3 consecutive years, with $21.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 7.18% to $21.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $94.4 million, a 13.51% decrease, with the full-year FY2025 number at $94.4 million, down 13.51% from a year prior.
  • Research & Development was $21.5 million for Q4 2025 at Metagenomi, down from $25.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.4 million in Q1 2024 to a low of $20.1 million in Q1 2023.
  • A 3-year average of $24.8 million and a median of $24.9 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 56.18% in 2024, then fell 20.53% in 2025.
  • Metagenomi's Research & Development stood at $24.8 million in 2023, then dropped by 6.43% to $23.2 million in 2024, then dropped by 7.18% to $21.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Research & Development are $21.5 million (Q4 2025), $25.3 million (Q3 2025), and $22.5 million (Q2 2025).